Fennec Pharmaceuticals Inc.

FRX.TOTSXHealthcare● Active

$12.44

$-0.28(-2.20%)

Market Cap$355535511

P/E Ratio—

52W High$14.24

52W Low$7.59

Avg Volume1K

Open$12.44

Beta1.08

Free Cash Flow Financials Revenue

Fennec Pharmaceuticals Inc. (FRX.TO) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

FRX.TO · free cash flow · updated Jun 8, 2026

Core FCF metrics

FRX.TO · FCF · TTM · margin & CAGR

Free cash flow was −$14.7M for FY2025 (fiscal year ending 2025-12-31), down 154.4% year-over-year The FCF margin was -32.3%.

FY2025 Free Cash Flow−$14.7M▼ -154.4% YoY

Trailing 12M (TTM)−$7.9Mtrailing 4 quarters sum

FCF Margin-32.3%−$14.7M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

FRX.TO · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$14.7M(0M)−$14.7M▼ 154.4%-32.3%

FY2024$27.0M(0M)$27.0M▲ +257.4%56.8%

FY2023−$17.1M(0M)−$17.1M▲ +5.1%-80.7%

FY2022−$18.1M(0M)−$18.1M▼ 27.0%—

FY2021−$14.2M(0M)−$14.2M▲ +8.8%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

FRX.TO · P/FCF · FCF yield · FCF per share

Fennec Pharmaceuticals Inc. (FRX.TO) reported negative free cash flow of −$0.01B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

FRX.TO · cash flow statement · operating / investing / financing

For FY2025, Fennec Pharmaceuticals Inc. generated −$14.7M in operating cash flow and spent 0M in capital expenditures, yielding −$14.7M in free cash flow.

Operating Activities

−$14.7M

Cash from core business operations

2025-12-31

Investing Activities

+$0.0M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$25.0M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$14.7M) − |CapEx| (0M) = FCF (−$14.7M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

FRX.TO vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Fennec Pharmaceuticals Inc.YOU

FRX.TO

−$14.7M-154.4%-32.3%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Fennec Pharmaceuticals Inc. (FRX.TO) reported free cash flow of −$14.7M for FY2025 (fiscal year ending 2025-12-31), down 154.4% year-over-year. The FCF margin was -32.3%.

Based on available data, Fennec Pharmaceuticals Inc. has maintained positive free cash flow for at least 1 fiscal year(s). FCF peaked at $27.0M in FY2024.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

FRX.TO free cash flow · 8 questions

Fennec Pharmaceuticals Inc. free cash flow was −$14.7M for FY2025, down 154.4% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$7.9M.

FRX.TO free cash flowFRX.TO FCFFRX.TO FCF 2025FRX.TO free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Fennec Pharmaceuticals Inc. · Fennec Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026